EQ 427 snags Series A
EG 427, a developer of pinpoint gene therapy, has secured 12 million euros in Series A funding.
EG 427, a developer of pinpoint gene therapy, has secured 12 million euros in Series A funding.
Copyright PEI Media
Not for publication, email or dissemination